|Bid||23.42 x 68800|
|Ask||23.78 x 1500|
|Day's range||23.42 - 23.80|
|52-week range||16.48 - 26.97|
|PE ratio (TTM)||28.73|
|Earnings date||28 Jul 2017|
|Dividend & yield||0.54 (1.85%)|
|1y target est||N/A|
BARCELONA, Spain, June 22, 2017 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines, and a leader in the development of innovative diagnostic solutions, is expanding its Texas-based Clinical Diagnostics Laboratory menu by launching therapeutic drug monitoring testing services. As the standard of care changes towards individualized patient care in diseases such as inflammatory bowel diseases, the clinicians' demand for monitoring biologic drugs is growing.
Celgene and Grifols are former leaders, but enough time has passed to give them a new shine.
Is Grifols a great pick from the value investor's perspective right now? Read on to know more.